NCT02402452View on ClinicalTrials.gov

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

September 28, 2015

Study Completion Date

September 28, 2015

Conditions
HCV Infection
Interventions
DRUG

Voxilaprevir

100 mg tablet administered orally

Trial Locations (4)

8011

Christchurch Clinical Studies Trust Ltd, Christchurch

32809

Orlando Clinical Research Center, Orlando

78215

Texas Liver Institute, San Antonio

81241

APEX GmbH, München

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02402452 - Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment | Biotech Hunter | Biotech Hunter